Non-exclusive Drug Rebate Agreement for Tacrolimus
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tacrolimus (ATC-Code nach WHO: L04AD02)
Opportunity Score
Why this score?
Opportunity
25 / 100
Complexity
30 / 100
Risk factors
No minimum volume guaranteed; quantities depend on prescription habits and patient demand. Revenue unpredictable.
Contract may be terminated early if exclusive rebate agreements are signed (typically 8-12 months after publication).
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Oct 31, 2026
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Non-exclusive drug rebate agreement for Tacrolimus (ATC L04AD02)
- Open-House model allowing any qualifying pharmaceutical entrepreneur to participate
Show full summary
Non-exclusive pharmaceutical rebate agreement for Tacrolimus (ATC L04AD02) via an Open-House model with AOK PLUS. No guaranteed volumes, no exclusivity. Multiple submission deadlines until October 2026. Confidentiality and specific declarations required.
Risks
No minimum volume guaranteed; quantities depend on prescription habits and patient demand. Revenue unpredictable.
Contract may be terminated early if exclusive rebate agreements are signed (typically 8-12 months after publication).
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Participation only via DTVP portal after obtaining access to project room
Administrative
- Absolute confidentiality of tender documents and rebate terms
- Electronic submission via DTVP communication function (not via bid tool)
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive Drug Rebate Agreement for Tacrolimus
Non-exclusive rebate agreement for Tacrolimus (ATC L04AD02) under §130a Abs. 8 SGB V. Open-House model, no exclusivity, no minimum volume. Contract ends 31 October 2026.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tacrolimus (ATC-Code nach WHO: L04AD02)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 28 Aug 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 565261-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
25 / 100
Complexity
30 / 100
Risk factors
No minimum volume guaranteed; quantities depend on prescription habits and patient demand. Revenue unpredictable.
Contract may be terminated early if exclusive rebate agreements are signed (typically 8-12 months after publication).
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications